Brief: Opzelura® (Ruxolitinib) Cream Becomes First Steroid-Free Topical Jak Inhibitor Approved In The European Union For Adults With Moderate Atopic Dermatitis
29/07/2026 11:50
BRIEF-Opzelura® (Ruxolitinib) Cream Becomes First Steroid-Free Topical Jak Inhibitor Approved In The European Union For Adults With Moderate Atopic Dermatitis July 29 (Reuters) - Incyte Corp INCY.O:
OPZELURA® (RUXOLITINIB) CREAM BECOMES FIRST STEROID-FREE TOPICAL JAK INHIBITOR APPROVED IN THE EUROPEAN UNION FOR ADULTS WITH MODERATE ATOPIC DERMATITIS
INCYTE - EUROPEAN COMMISSION APPROVES OPZELURA (RUXOLITINIB) CREAM FOR MODERATE ATOPIC DERMATITIS IN ADULTS
Source text: ID:nBw88YmC1a
Further company coverage: INCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler